Document Detail

Serum IL-6: a candidate biomarker for intracranial pressure elevation following isolated traumatic brain injury.
Jump to Full Text
MedLine Citation:
PMID:  20222971     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Increased intracranial pressure (ICP) is a serious, life-threatening, secondary event following traumatic brain injury (TBI). In many cases, ICP rises in a delayed fashion, reaching a maximal level 48-96 hours after the initial insult. While pressure catheters can be implanted to monitor ICP, there is no clinically proven method for determining a patient's risk for developing this pathology.
METHODS: In the present study, we employed antibody array and Luminex-based screening methods to interrogate the levels of inflammatory cytokines in the serum of healthy volunteers and in severe TBI patients (GCS<or=8) with or without incidence of elevated intracranial pressure (ICP). De-identified samples and ELISAs were used to confirm the sensitivity and specificity of IL-6 as a prognostic marker of elevated ICP in both isolated TBI patients, and polytrauma patients with TBI.
RESULTS: Consistent with previous reports, we observed sustained increases in IL-6 levels in TBI patients irrespective of their ICP status. However, the group of patients who subsequently experienced ICP >or= 25 mm Hg had significantly higher IL-6 levels within the first 17 hours of injury as compared to the patients whose ICP remained <or=20 mm Hg. When blinded samples (n = 22) were assessed, a serum IL-6 cut-off of <5 pg/ml correctly identified 100% of all the healthy volunteers, a cut-off of >128 pg/ml correctly identified 85% of isolated TBI patients who subsequently developed elevated ICP, and values between these cut-off values correctly identified 75% of all patients whose ICP remained <or=20 mm Hg throughout the study period. In contrast, the marker had no prognostic value in predicting elevated ICP in polytrauma patients with TBI. When the levels of serum IL-6 were assessed in patients with orthopedic injury (n = 7) in the absence of TBI, a significant increase was found in these patients compared to healthy volunteers, albeit lower than that observed in TBI patients.
CONCLUSIONS: Our results suggest that serum IL-6 can be used for the differential diagnosis of elevated ICP in isolated TBI.
Authors:
Georgene W Hergenroeder; Anthony N Moore; J Philip McCoy; Leigh Samsel; Norman H Ward; Guy L Clifton; Pramod K Dash
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't     Date:  2010-03-11
Journal Detail:
Title:  Journal of neuroinflammation     Volume:  7     ISSN:  1742-2094     ISO Abbreviation:  J Neuroinflammation     Publication Date:  2010  
Date Detail:
Created Date:  2010-04-13     Completed Date:  2010-07-01     Revised Date:  2013-05-30    
Medline Journal Info:
Nlm Unique ID:  101222974     Medline TA:  J Neuroinflammation     Country:  England    
Other Details:
Languages:  eng     Pagination:  19     Citation Subset:  IM    
Affiliation:
The Department of Neurobiology and Anatomy, The University of Texas Medical School, Houston, Texas, USA. Georgene.W.Hergenroeder@uth.tmc.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
APACHE
Adolescent
Adult
Aged
Biological Markers / blood*
Brain Injuries / blood*,  complications
Cytokines / blood
Enzyme-Linked Immunosorbent Assay
Female
Fractures, Bone / blood
Glasgow Coma Scale
Humans
Injury Severity Score
Interleukin-6 / blood*
Intracranial Hypertension / blood*,  etiology
Male
Middle Aged
Multiple Trauma / blood
Predictive Value of Tests
Prognosis
Reagent Kits, Diagnostic
Recruitment, Neurophysiological / physiology
Reproducibility of Results
Tomography, X-Ray Computed
Young Adult
Chemical
Reg. No./Substance:
0/Biological Markers; 0/Cytokines; 0/Interleukin-6; 0/Reagent Kits, Diagnostic
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Full Text
Journal Information
Journal ID (nlm-ta): J Neuroinflammation
ISSN: 1742-2094
Publisher: BioMed Central
Article Information
Download PDF
Copyright ?2010 Hergenroeder et al; licensee BioMed Central Ltd.
open-access:
Received Day: 19 Month: 11 Year: 2009
Accepted Day: 11 Month: 3 Year: 2010
collection publication date: Year: 2010
Electronic publication date: Day: 11 Month: 3 Year: 2010
Volume: 7First Page: 19 Last Page: 19
ID: 2853529
Publisher Id: 1742-2094-7-19
PubMed Id: 20222971
DOI: 10.1186/1742-2094-7-19

Serum IL-6: a candidate biomarker for intracranial pressure elevation following isolated traumatic brain injury
Georgene W Hergenroeder12 Email: Georgene.W.Hergenroeder@uth.tmc.edu
Anthony N Moore3 Email: Anthony.N.Moore@uth.tmc.edu
J Philip McCoy, Jr4 Email: mccoyjp@nhlbi.nih.gov
Leigh Samsel4 Email: samsell@mail.nih.gov
Norman H Ward, III1 Email: Norman.Ward@uth.tmc.edu
Guy L Clifton1 Email: guyclifton@gmail.com
Pramod K Dash3 Email: p.dash@uth.tmc.edu
1The Department of Neurosurgery, The University of Texas Medical School, Houston, Texas, USA
2The Vivian L Smith Center for Neurologic Research, The University of Texas Medical School, Houston, Texas, USA
3The Department of Neurobiology and Anatomy, The University of Texas Medical School, Houston, Texas, USA
4National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA

Background

Traumatic brain injury (TBI) is a leading cause of morbidity and mortality among civilian and military populations. The initial injury sets in motion a number of cellular and molecular events leading to the development of secondary processes that profoundly influence outcome. One of the major secondary pathologies is elevated intracranial pressure (ICP). If not maintained below 20 mm Hg, elevated ICP can cause poor cerebral perfusion, brain herniation, and death. In many cases, ICP rises in a delayed manner, reaching its peak level between days 3-5 post-TBI [1]. Although no prophylactic treatment is currently available to prevent elevated ICP, neurointensivists and neurosurgeons often use sedatives, mannitol, hypertonic saline, cerebrospinal fluid drainage, decompressive craniectomy, and/or barbiturate-induced coma to manage this condition. Therefore, the identification of prognostic biomarkers that can predict which patients are at risk of developing high ICP would help in managing severe TBI patients.

Previous studies have implicated inflammatory processes in ICP elevation [2,3]. Both pro- and anti-inflammatory cytokines have been reported to change as a result of TBI and their combined action is thought to determine the overall degree of inflammation [4]. Interleukin-6 (IL-6) is a 20-30 kDa cytokine with pleiotropic properties that has been shown to be a biomarker associated with various disease states. For example, high serum IL-6 correlates with coronary instability and carotid plaques, has been shown to be a prognostic marker for septic shock, and is an indicator of outcome in severe intra-abdominal sepsis [5-7]. In TBI, a relationship has been reported between the transcranial IL-6 gradient (venous-arterial) at the time of admission and survivability [8]. In addition, a recent multiplex analysis of putative serum biomarkers identified IL-6 as a marker of inflicted pediatric TBI [9]. Although these studies support the premise that inflammation-related proteins such as IL-6 are elevated following TBI, it has not been examined if the magnitude or duration of induction correlates with the development of ICP.

In the present study, we utilized two screening methods, antibody arrays and multiplexing, to evaluate the levels of interleukin family members in the serum of healthy volunteers and in severe TBI patients (GCS?8) with and without incidence of ICP. Consistent with a number of previous reports, we observed elevated IL-6 levels in TBI patients as compared to healthy volunteers. Interestingly, the group of TBI patients who subsequently developed ICP ? 25 mm Hg had significantly higher serum IL-6 levels within the first 17 hours of injury as compared to the patients whose ICP remained ?20 mm Hg during their hospital stay. However, in polytrauma patients with TBI, serum IL-6 levels were unable to differentiate between the two groups. IL-6 levels in patients with orthopedic injury were found to be higher than those recorded in healthy volunteers, but lower than seen in the TBI patients. Taken together, our results suggest that for patients with isolated TBI, serum IL-6 is a good prognostic biomarker for predicting subsequent ICP elevations.


Methods
Recruitment and sample collection

All protocols regarding the use of human subjects were reviewed and approved by the University of Texas Committee for the Protection of Human Subjects, and were in compliance with the Helsinki Declaration. Blood samples were obtained specifically for the purpose of this study and were coded to protect confidentiality. Non-trauma volunteers were consented and enrolled by the University of Texas Clinical Research Unit at Memorial Hermann Hospital (Houston, TX). To be included in the study, orthopedic injury patients admitted to the Memorial Hermann Hospital Emergency Department had to have a radiographically confirmed fracture, no head trauma, no other known inflammatory process or infection, no history of neurological or psychiatric disorders, and no alcohol or drug dependency. Orthopedic injury subjects were consented and a one-time blood draw within 24 hr of the injury was taken. TBI patients (14-65 years old) admitted to the adult neurotrauma intensive care unit (NTICU) of Memorial Hermann Hospital who had Glasgow Coma Scale (GCS) scores ?8 and planned placement of an ICP monitor were recruited, and consented (through their next-of-kin) for participation in this study. ICP measurements were measured continuously and recorded hourly from the time of monitor placement. Elevated ICP was defined as a ?25 mm Hg measurement for at least 5 minutes that occurred either twice in a 24 hr period, or on two consecutive days. No change in ICP was defined as an ICP level of ?20 mmHg throughout the 5 day study period. Patients whose ICP fell between 20-25 mmHg on any of the sampling days were not included in the present study in order to provide a clear separation between the two injury groups. An initial blood draw was obtained at the earliest possible time after admission, patient stabilization, and informed consent was obtained. To minimize interference with clinical management, subsequent blood samples were drawn after morning rounds were completed (i.e. every 24 hours for first five days of hospital admission). Relevant medical data was recorded and coded to match the extracted blood sample. Serum was isolated by centrifugation at 4?C using serum separator tubes (Becton Dickinson, Franklin Lakes, NJ) as described by the vendor. Aliquots were prepared and frozen at -80?C until needed.

Patient management

All patients admitted to the NTICU of Memorial Hermann Hospital received standard care based on the types and severities of their injuries. Patients were managed to avoid hypoxia and hypotension, and to attempt to maintain adequate cerebral blood flow (e.g., systolic pressure above 90 mm Hg and a cerebral perfusion pressure (CPP) of at least 60 mm Hg.). Head computed tomography (CT) scans were performed on presentation to the Emergency Department and repeated within approximately 6 hours. Subsequent CTs were performed based on the patient's neurological status. Intracranial pressure monitors were placed in those with a GCS ? 8, or those with significant findings on head CT who in the opinion of the attending neurosurgeon required intracranial pressure monitoring. Any patient with an operative lesion was transferred to the operating room emergently. The decision to remove a bone flap was made by the attending neurosurgeon at his discretion. Medications to prevent seizures were given prophylactically for the first 7 days of hospitalization. The patient's temperature was controlled to prevent the patient from becoming hyperthermic. Patient's intake and output were monitored to assure that the patient received adequate fluid volume. Sedation and analgesics were used in all severe TBI patients. Drainage of CSF, mannitol and/or hypertonic saline was used, as required, to lower intracranial pressure. Refractory elevated ICP typically went through the treatment continuum of sedation, mannitol, CSF drainage, paralytics, barbiturate coma, and decompressive craniectomy. With the exception of those treatments initiated to control intracranial pressure (e.g. mannitol, cranieotomy, etc.), the care did not differ between the two study groups.

Patient assessments and classifications

Acute Physiology and Chronic Health Evaluation II (APACHE II), GCS and Injury Severity Score (ISS). APACHE II is designed to measure the severity of disease for newly admitted ICU patients [10]. The worst value for each component of the scale in the first 24 hours of ICU admission was collected. GCS is a neurological assessment routinely used in clinical care and neurosurgical research [11]. All injuries were classified according to body region and given an abbreviated injury score (AIS, The Abbreviated Injury Scale, 1990 Revision, Update 98) from 1 to 6 according to standardized definitions (a score of 6 indicates death). The worst three AIS scores in different body regions were squared and summed to calculate the ISS. The ISS correlates linearly with mortality, morbidity, length of hospital stay, and other measures of injury severity [12]. Polytrauma was defined as a head injury along with an AIS score ?3 in a body region other than the head, neck or face.

Human cytokine array

The levels of inflammation-related factors were assessed using the Cytokine Array 2000 series (Ray Biotech, Norcross, GA) as described by the vendor. Serum samples (n = 14/group) collected within the first 24 hr of injury were chosen from TBI patients whose ICP remained ?20 mm Hg throughout the study period, and from TBI patients whose maximum recorded ICP ? 25 mm Hg. Samples were divided (n = 7/time point) based on their collecting time into either 10 hr (? 4 hr) or 20 hr (? 4 hr) groups, then pooled. Pooled samples from age-, race- and gender-matched healthy volunteers served as baseline controls. The membranes were blocked against non-specific binding for 2 hr using the 1? blocking buffer provided in the assay kit. Pooled serum samples were diluted 10-fold in 1? blocking buffer and incubated on individual membranes overnight at 4?C with gentle shaking. Following washing, biotinylated antibodies were added for 2 hr. The binding of the biotinylated antibodies was detected using a horseradish peroxidase-streptavidin complex and a chemilumenescent substrate. Signals were captured on BioMax light film (Perkin-Elmer, Waltham, Massachusetts) and analyzed using Image J densitometric software. All groups were assessed simultaneously so that they were represented on the same film. Multiple exposures were generated to ensure the linearity of the signals. The cumulative optical densities of the resultant spots on each membrane were summed and compared across membranes for normalization purposes. Antibodies against each analyte were represented in duplicate spots on each membrane, the optical densities of which were averaged. Each pooled sample was tested on two independent arrays.

Luminex

The levels of IL-1?, IL-1?, IL-2, IL-4, IL-5, IL-6, IL-10, IL-17, and IL-1ra were determined using Luminex and kits obtained from R&D Systems (Minneapolis, MN) and the procedures were conducted as recommended by the vendor. Briefly, a standard curve for each of the target proteins was prepared by serial dilution in assay buffer. Serum samples were diluted 1:4. Standards and samples were incubated in a 96-well filter-bottom plate with target-specific microparticles for 2 hr at room temperature with shaking. Following the incubation, microparticles were washed 3 times using the wash buffer provided in the kit and a vacuum manifold. Biotinylated antibodies were added and incubated for 1 hr, and detected using a streptavidin-phycoerythrin conjugate. Following extensive washing, samples were analyzed on a Luminex plate reader. All samples were analyzed in duplicate and the concentrations calculated by comparison to the appropriate standard curve.

Enzyme-linked immunosorbent assays (ELISAs)

To test the predictive power of changes in serum IL-6 proteins, sandwich ELISAs were performed using samples collected during the first 24 hr of injury. Samples from healthy volunteers were used as controls. Samples were coded so that the experimenter was unaware of the group designation during the procedure. A standard curve was prepared by serial dilution of purified recombinant protein supplied with the assay (R&D systems, Minneapolis, MN). Standards and serum samples (in triplicate) were added to a 96-well plate containing immobilized antibodies specific to IL-6. Samples were incubated at room temperature for 2 hours, with gentle shaking. Following extensive washing, bound IL-6 was detected using an HRP-conjugated polyclonal antibody against the target protein. The detection antibody was incubated for 2 hr at room temperature, and detected using 2,2'-Azino-bis-(3-ethylbenzthiazoline-6-sulfonic acid) and 3% H2O2. The reaction was terminated by the addition of sulfuric acid provided in the kit. The resultant optical density was detected using a microplate reader at 450 nm with a wavelength correction reading at 540 nm. The concentrations of the unknowns were calculated from the standard curve using SigmaPlot (Systat Software, Inc, San Jose CA).

Statistical analysis

A power analysis based on approximated magnitudes of change and technique reproducibility was performed a priori to estimate the group sizes expected to provide statistically significant results. All data was assessed using a Kolmogorov-Smirnov test to determine normal distribution. Time course data was compared using a two-way ANOVA. Data for two-group or multiple group comparisons at a single time point were analyzed using a Students t-test or one-way ANOVA, respectively. Any data that did not have a normal distribution was assessed using non-parametric measures (e.g. ANOVA on Ranks). Data are presented as the mean ? SEM unless otherwise indicated, and the median value and data range are provided where appropriate.


Results
Interleukin family member expression in the serum of TBI patients with/without elevated ICP

To determine if the serum levels of interleukin family members can be used to differentiate TBI patients based on whether or not they will have a subsequent elevation in ICP, two screening approaches were utilized: 1) antibody arrays using pooled serum samples from healthy volunteers and TBI patients with/without incidence of ICP ? 25 mm Hg, and 2) Luminex analysis of individual serum samples from independent patients belonging to the same groups.

Experiment 1: Antibody array

Using the recorded ICP values for the TBI patients enrolled in this study, patients were divided into either elevated ICP (ICP ? 25 mm Hg) or no-ICP groups (ICP ? 20 mm Hg). Age-, race- and gender-matched healthy volunteers were selected and used as controls. The demographics of the patients used in this study are listed in Table 1. Figure 1A shows that when the maximum recorded ICP levels each day were plotted as a function of time, the elevated ICP group had a delayed increase in ICP, reaching a maximum between days 3 and 5 post-injury. By comparison, the patients without incidence of elevated ICP had pressure values that remained below the treatment level of 20 mm Hg throughout the study period. Although it appears that the initial ICP values in the ICP ? 25 mm Hg group are higher than those detected in the ICP ? 20 mm Hg group, correlation analysis revealed that initial ICP is not a strong predictor of subsequent ICP elevations. When the ICP values were analyzed to determine if there was a correlation between initial ICP value (day 1) and those recorded on days 3-5 (the time points at which ICP ? 25 mm Hg were observed), correlation coefficients of 0.596 (day 3), 0.241 (day 4), and 0.173 (day 5) were calculated.

As the principle aim of the current study was to determine if the initial levels of interleukin family members could be used to identify patients at risk for developing elevated ICP, serum samples from each of the groups were further subdivided based on their collection time. Pools of samples were prepared corresponding to either 10 ? 4 hr or 20 ? 4 hr post-injury (n = 7/group), and applied to a cytokine array as directed by the vendor (Ray Biosciences). Figure 1B shows representative images of the resultant blots indicating the relative immunoreactivities for IL-10, IL-13, IL-15, IL-16, IL-1?, IL-1?, Il-1ra, IL-2, IL-3, IL-4, Il-5, IL-6 and IL-7. Quantification of the optical densities for these cytokines revealed that while the serum levels of IL-6 were dramatically elevated in both TBI groups relative to that observed in the healthy volunteers, the magnitude of increase seen in the TBI patients with ICP ? 25 mm Hg was significantly higher than that seen in the TBI patients whose ICP remained ?20 mm Hg throughout the study period (relative immunoreactivity: healthy volunteers = 100.0 ? 16.96%, ICP ? 20 mm Hg = 217.5 ? 26.95%, ICP ? 25 mm Hg = 842.7 ? 112.96%; significant interaction by two-way ANOVA F(1,8) = 12.835, P = 0.007) (Figure 1C). No significant change was detected in any of the other cytokines interrogated.

Experiment 2: Luminex

Since the above analysis was performed using pooled samples, it raised the possibility that a large increase in IL-6 levels within a few of the patients would have been sufficient to increase the level of this protein in the entire pooled sample. To address this concern, Luminex analysis was performed using individual serum samples from independent study subjects. The demographics of the subjects used in this study are presented in Table 2. Figure 2A shows that these patients, similar to those chosen for the antibody array screen, had ICP levels that either remained ?20 mm Hg throughout the study period, or had a delayed increase in ICP that necessitated intervention. As in Experiment 1, the ICP values recorded for these patients on day1 was found to not be a strong predictor of the maximum ICP values recorded on day3 (correlation coefficient = 0.626), day4 (correlation coefficient = 0.353), or day5 (correlation coefficient = 0.152).

Luminex analysis was performed using analyte kits available for multiplexing from R&D Systems (Minneapolis, MN). The interleukin family members interrogated were IL-10, IL-17, IL-1?, IL-1?, IL-1ra, IL-2, IL-4, IL-5, and IL-6. Standard curves for each of the analytes were generated using purified proteins supplied by the vendor, and used to calculate the concentration of the target protein in each of the individual samples. A representative standard curve generated for IL-6 is shown in Figure 2B. Similar to that observed using the antibody array, when the levels of serum IL-6 were compared between the healthy volunteers and TBI patients, a dramatic increase in the level of this protein was observed as a result of injury (Figure 2C). Of importance is the observation that the initial levels of IL-6 recorded in TBI patients that would subsequently develop elevated ICP were significantly higher than that observed in TBI patients whose ICP remained below 20 mm Hg (group main effect by two-way ANOVA F(1,3) = 6.541, P = 0.016). When organized according to time from ICP (the day ICP was first recorded to exceed 25 mm Hg was designated as day 0), the significant increase in IL-6 levels was observed to occur, on average, two days prior to the recorded time of ICP elevation (group main effect by two-way ANOVA F(1,3) = 4.040, P = 0.049) (Figure 2D). All other cytokines, with the exception of IL-1ra, were below the detection limit of the Luminex assay. Serum IL-1ra (data not shown), although elevated as a result of TBI, was not significantly different between the ICP groups.

Prognostic accuracy of IL-6 for predicting ICP in TBI patients

Based on the results of the Luminex screening, cut-off values of ?128 pg/ml (ICP ? 25 mm Hg), 5.1-127.9 pg/ml (for ICP ? 20 mm Hg), and ?5 pg/ml (for healthy volunteers) serum IL-6 were identified as being able to stratify the patient groups. To test the accuracy of these cut-off values, ELISAs were performed using samples that were blinded as to their group designations. Prior to initiating these studies, randomly chosen serum samples used for Luminex analysis were re-probed using an IL-6 ELISA to determine the consistency of the measurements. Table 3 shows the recorded values for each of the samples. The table shows that 7 out of 8 (87.5%) samples identified as having serum IL-6 values ?128 pg/ml by Luminex also giving values ?128 pg/ml by ELISA. Similarly, 75% of samples with serum IL-6 concentrations between 5.1-127.9 pg/ml were found to be in this range by ELISA.

De-identified samples from healthy volunteers and TBI patients, whose first sample draw occurred during the first 17 hr of injury, were analyzed for IL-6 levels using ELISA. This time point was chosen as it represented the latest time at which IL-6 serum concentrations were found to be consistently elevated in the ICP ? 25 mm Hg group by the antibody array and Luminex analyses. Predetermined cut-off values, based on the Luminex analysis, of ?5 pg/ml for healthy volunteers, 5-127.9 pg/ml for ICP ? 20 mm Hg and ?128 pg/ml for ICP ? 25 mm Hg, were used to classify the de-identified samples. Table 4 shows the measured concentrations of IL-6 in these samples, along with the predicted and actual group designations. The results show that serum IL-6 concentrations could be used to correctly classify 7 of 7 healthy volunteers, and 15 of 15 injured patients. Of the injured patients, 6 of 8 were correctly identified as belonging to the ICP ? 20 mm Hg group, and 6 of 7 correctly identified as having a subsequent ICP elevation (85.7% sensitivity, 75% specificity) at the cut-off values employed. Compilation of all the recorded IL-6 values for the ICP ? 20 mm Hg and ICP ? 25 mm Hg groups yielded a receiver operator characteristic curve with an area under the curve of 0.81, suggesting that IL-6 is a good prognostic marker for ICP in isolated brain injury.

We next questioned if the increase in IL-6 levels observed in patients whose ICP subsequently elevated to ?25 mm Hg could be correlated to the degree (magnitude, frequency or duration) of ICP elevation. ICP profiles from individual patients were generated using data recorded hourly by the nursing staff. Figure 3A shows representative ICP profiles from TBI patients whose ICP remained below the threshold for therapeutic intervention (20 mm Hg; dotted line). Patients with elevated ICP, by comparison, had several ICP spikes that necessitated ICP management (Figure 3B). To determine if the degree of ICP elevation correlated with initial IL-6 values, the number of spikes over 20 mm Hg, the maximum recorded ICP value, and the area under the curve (AUC) for the ICP values over 20 mm Hg were calculated for the 5 day monitoring period. Correlation analysis revealed that there was no correlation between the level of IL-6 and either the number of ICP events (correlation coefficient = -0.23), the maximum ICP value (correlation coefficient = 0.20), or the AUC (correlation coefficient = -0.24). However, since all the patients in this study received treatment if their ICP passed 20 mmHg, the ICP profiles recorded (magnitude, frequency and duration) are likely to have been influenced by the treatments being instituted for each patient.

Prognostic accuracy of IL-6 for predicting ICP in polytrauma patients

As TBI often occurs in the presence of bodily trauma, and serum IL-6 levels have been shown to increase following other injuries, we questioned if the prognostic accuracy of this biomarker in identifying TBI patients at risk for developing elevated ICP would be compromised by polytrauma. Polytrauma was defined as a head injury along with an injury to another body region that received an AIS score ?3. De-identified samples from these patients were analyzed for serum IL-6 content and group designations assigned using the aforementioned cut-off values. The results presented in the Table 5 show that serum IL-6 concentrations could be used to only correctly classify 6 of the 11 polytrauma patients tested (54.5%) based on their ICP status.

Increases in IL-6 levels in patients with orthopedic injury

The loss of prognostic accuracy of serum IL-6 in polytrauma patients suggests that the presence of other bodily injuries may be altering serum IL-6 levels. To address this possibility, we measured its concentration in patients with orthopedic injury (n = 7) in the absence of a TBI diagnosis (GCS = 15). Serum samples from these patients were collected within 24 hrs of injury. Table 6 shows the type of injury and serum IL-6 concentrations recorded in these individuals. On average, serum IL-6 was found to be significantly elevated as a result of orthopedic injury as compared to healthy volunteers (healthy volunteers = 0.98 ? 0.37 pg/ml vs orthopedic injury = 35.09 ? 14.02 pg/ml, p = 0.002) (Figure 4A). Although elevated, these levels were found to be significantly lower than those detected in isolated TBI (one-way ANOVA on Ranks: H = 12.076, P = 0.002; Figure 4B) and in polytrauma patients (one-way ANOVA on Ranks: H = 8.157, P = 0.017; Figure 4C). Interestingly, while the orthopedic injury patients were found have a serum IL-6 levels that were significantly lower than both polytrauma groups (i.e. ICP ? 20 mm Hg and ICP ? 25 mm Hg), they were not different than that observed in the isolated TBI patients whose ICP remained lower than 20 mm Hg (Figure 4B and 4C). This suggests a general increase in serum IL-6 levels as a result of polytrauma.


Discussion

In the present study, we employed two independent cytokine screening platforms to identify serum IL-6 as a prognostic biomarker for ICP elevation following TBI. To the best of our knowledge, this is the first report to indicate that serum IL-6 levels can be used as a prognostic biomarker for elevated ICP in patients with isolated TBI. Although we observed a change in serum IL-6 levels in TBI patients, the present study does not indicate if the increased IL-6 we measured originated in the injured brain, or was the result of a peripheral response to the injury. Previous studies have shown that injury to the brain can cause both localized and systemic inflammatory reactions [13-15]. In the brain, neurons, astrocytes and microglia have all been shown to express IL-6 [16-19], and it has been argued that this production is the main source of IL-6 in the serum following TBI. For example, arterial and jugular differences in IL-6 concentration have been observed in TBI patients [8,20]. Furthermore, IL-6 is the cytokine that is present in the highest concentration in human CSF after TBI [21], reaching peak concentrations of up to 30,000 pg/ml [22]. By comparison, peak serum concentrations of IL-6 have been reported to only reach 1090 pg/ml during the same time period [23]. Taken together, these studies suggest that the increase in serum IL-6 levels we observed may have originated in the injured brain, rather than the result of a peripheral response to the injury.

A number of studies have reported that increased IL-6 levels in the CSF correlate with favorable outcome after brain injury [8,24-26]. For example, an in vivo microdialysis study has shown that increased parenchymal IL-6 levels following TBI correlates with survival and improved Galsgow Outcome Score (GOS) [26]. In addition, Chiaretti et al., [27] reported that early increases in CSF IL-6 levels are associated with improved neurologic outcome in children with severe TBI. In contrast to these influences of IL-6 in the CSF, elevated serum IL-6 has been shown to correlate with multi-organ failure and death following TBI [28,29], and is associated with poor neurological outcome following hemorrhagic stroke [30]. Serum levels of IL-6 ranging from 663.3 pg/mL to 1060.9 pg/mL have been documented to occur following brain death [31]. In non-CNS diseases, high serum IL-6 levels have been correlated to poor survival of breast cancer [32], are thought to be proatherogenic [33], and are strong predictors of mortality in patients with end-stage renal disease [34]. The reason for these apparent differential effects of IL-6 is not known, but may be dependent on the affected cell types. For example, IL-6 has been reported to reduce glutamate- and NMDA-induced neuronal death [35,36], and its loss is associated with increased oxidative stress and neurodegeneration after injury [37]. In contrast, transgenic mice overexpressing IL-6 in glial cells show ataxia, seizures and extensive neurodegeneration [38]. Although the relationship between high serum IL-6 and the development of ICP is not clear at present, our findings are consistent with previous observations that high serum IL-6 levels are often associated with poor outcome. Future basic and clinical studies using IL-6 receptor blockers such as Tocilizumab (an anti-IL6R used to treat rheumatoid arthritis) are needed to establish a role for IL-6 in the progression of this secondary pathology.

In polytrauma patients, IL-6 can also be released into the circulation as a result of injury to other organs. Many cell types including monocytes, macrophages, fibroblast, keratinocytes, smooth muscle cells, T cells, and B cells have all been shown to increase IL-6 production in response to injury [39-43]. This extracranial production would be expected to further elevate serum IL-6 and exacerbate outcome. Consistent with this, Hensler et al., [44] reported that the serum concentrations of a number of cytokines, including IL-6, in patients with multiple injuries with TBI is higher than that observed in isolated TBI. Although we did not observe a significant group-wide increase in IL-6 levels as a result of polytrauma, the presence of other injuries appears to have reduced the prognostic accuracy of this marker in identifying patients at risk for developing elevated ICP. In support of this possibility, we observed that patients with orthopedic injuries in the absence of TBI had significantly higher serum IL-6 levels than those observed in healthy volunteers. Extracranial sources of IL-6 such as those observed in the orthopedic injury patients may have contributed to the increase in IL-6 levels seen in polytrauma patients whose ICP remained below 20 mm Hg (Figure 3C), making them indistinguishable from patients whose ICP ? 25 mm Hg. However, due to the variety of extracranial injuries observed in the polytrauma patients (e.g. ruptured spleen, burns, fractures, etc.), it is not clear if different cut-off values, time of sampling, or further sub-classification based on type(s) of bodily injury, could be employed to increase the sensitivity of this marker for use in polytrauma.

Although IL-6 appears to lack sufficient specificity to diagnose or detect brain injury, our study suggests that it may have utility as a biomarker capable of predicting patients with isolated TBI who are at risk for developing elevated ICP, being able to identify these patients up to 2 days prior to the recorded increases in ICP. Previous studies have indicated that the CNS specific proteins glial fibrillary acidic protein (GFAP), cleaved tau (C-tau) and neuron-specific enolase (NSE) also have some prognostic capacity in identifying TBI patients at risk for developing elevated ICP [45-47]. For example, Zemlan et al., have reported that a high initial C-tau level in the CSF of TBI patients is a good predictor of elevated ICP [45]. However, recent studies have shown that the process of CSF drainage can not only change ICP, but depending on the method of drainage (continuous versus intermittent), can also dramatically influence CSF biomarker levels [48]. In the serum, S100B and GFAP concentrations have been shown to be lower in patients with ICP < 25 mm Hg than in patients with ICP > 25 mm Hg [46]. While S100B has been demonstrated to have extracranial sources, serum GFAP levels are not increased by non-head injuries [46,49]. In addition to these CNS proteins, we have recently demonstrated that the levels of serum ceruloplasmin, the major copper carrier in the blood, transiently decrease in TBI patients who will develop elevated ICP, and that this reduction can be used as a sensitive prognostic marker of subsequent ICP increases [50]. It is therefore suggested that a combination of biomarkers could be developed that couples IL-6, other identified biomarkers, and routine diagnostic evaluation of patient injuries, to create a biomarker signature that predicts the occurrence of elevated ICP with both high sensitivity and specificity.


Conclusions

Our results indicate that the initial level of serum IL-6 (within 17 hours of injury) can be used to identify isolated TBI patients at risk for developing elevated intracranial pressure. As this increase was observed, on average, 2 days prior to the recorded increase in ICP, this would allow sufficient time for physicians and caretakers to allocate resources and/or transport the patient so that appropriate ICP management procedures can be employed.


List of abbreviations

AIS: abbreviated injury scale; c-tau: cleaved tau; GCS: Glasgow coma scale; GFAP: glial fibrillary acidic protein; ELISA: enzyme-linked immunosorbent assay; ICP: intracranial pressure; TBI: traumatic brain injury.


Competing interests

The authors declare that they have no competing interests.


Authors' contributions

GWH contributed to the overall design of the study and assisted in the interpretation of the resultant data, was responsible for maintaining the standards and upholding the reporting requirements for the use of human subjects, drafted and revised the article. ANM contributed to the acquisition and analysis of all data presented in the manuscript, prepared the presentation materials and performed the statistical analyses, drafted and revised the article. JPM contributed to the design of the Luminex experimentation and assisted in the analysis of the resultant data, and revised the article. LS contributed to the acquisition and analysis of the Luminex data. NHW contributed to the acquisition of the serum samples and analysis of the patient data used in this study. GLC made substantial contributions to the conception and overall design of the study, and revised the article. PKD made substantial contributions to the conception and overall design of the study, in the interpretation of the resultant data, drafted and revised the article. All authors have read and approved the final version of the manuscript.


Acknowledgements

The authors thank Dr. Shibani Pati and Dr. Aarif Khakoo for their assistance in facilitating this project. We would like to thank the Memorial Hermann Hospital Neurotrauma ICU, and Trauma and EMS coders; and Elizabeth Jones, MD, Molly S. Bray, PhD, Brian McFarlin, PhD, Ian Turpin, and Madelene Ottosen, MSN RN for assistance with recruiting orthopedic patients and healthy volunteers for the study. This work was supported in part by a grant from Mission Connect/TIRR Foundation and by the Intramural Research Program of NHLBI. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.


References
Stocchetti N,Colombo A,Ortolano F,Videtta W,Marchesi R,Longhi L,Time course of intracranial hypertension after traumatic brain injuryJ NeurotraumaYear: 2007241339134610.1089/neu.2007.030017711395
Dearden NM,Mechanisms and prevention of secondary brain damage during intensive careClin NeuropatholYear: 1998172212289707338
Jantzen JP,Prevention and treatment of intracranial hypertensionBest Pract Res Clin AnaesthesiolYear: 20072151753810.1016/j.bpa.2007.09.00118286835
Kadhim HJ,Duchateau J,Sebire G,Cytokines and brain injury: invited reviewJ Intensive Care MedYear: 20082323624910.1177/088506660831845818504260
Libby P,Inflammation in atherosclerosisNatureYear: 200242086887410.1038/nature0132312490960
Yamagami H,Kitagawa K,Nagai Y,Hougaku H,Sakaguchi M,Kuwabara K,Higher levels of interleukin-6 are associated with lower echogenicity of carotid artery plaquesStrokeYear: 20043567768110.1161/01.STR.0000116876.96334.8214752126
Patel RT,Deen KI,Youngs D,Warwick J,Keighley MR,Interleukin 6 is a prognostic indicator of outcome in severe intra-abdominal sepsisBr J SurgYear: 1994811306130810.1002/bjs.18008109147953393
Minambres E,Cemborain A,Sanchez-Velasco P,Gandarillas M,az-Reganon G,Sanchez-Gonzalez U,Correlation between transcranial interleukin-6 gradient and outcome in patients with acute brain injuryCrit Care MedYear: 20033193393810.1097/01.CCM.0000055370.66389.5912627008
Berger RP,Ta'asan S,Rand A,Lokshin A,Kochanek P,Multiplex assessment of serum biomarker concentrations in well-appearing children with inflicted traumatic brain injuryPediatr ResYear: 2008659710210.1203/PDR.0b013e31818c7e27
Knaus WA,Draper EA,Wagner DP,Zimmerman JE,APACHE II: a severity of disease classification systemCrit Care MedYear: 19851381882910.1097/00003246-198510000-000093928249
Teasdale G,Jennett B,Assessment of coma and impaired consciousness. A practical scaleLancetYear: 19742818410.1016/S0140-6736(74)91639-04136544
Association for the Advancement of Automotive MedicineAbbreviated Injury Scale (AIS) 2005 - Update 2008Year: 2008Barrington, IL: AAAM Publications
Bell MJ,Kochanek PM,Doughty LA,Carcillo JA,Adelson PD,Clark RS,Comparison of the interleukin-6 and interleukin-10 response in children after severe traumatic brain injury or septic shockActa Neurochir Suppl (Wien)Year: 1997709697
Kossmann T,Hans VH,Imhof HG,Stocker R,Grob P,Trentz O,Intrathecal and serum interleukin-6 and the acute-phase response in patients with severe traumatic brain injuriesShockYear: 1995431131710.1097/00024382-199511000-000018595516
Cui X,Kalsotra A,Robida AM,Matzilevich D,Moore AN,Boehme CL,Expression of cytochromes P450 4F4 and 4F5 in infection and injury models of inflammationBiochim Biophys ActaYear: 2003161932533112573492
Basu A,Krady JK,O'Malley M,Styren SD,DeKosky ST,Levison SW,The type 1 interleukin-1 receptor is essential for the efficient activation of microglia and the induction of multiple proinflammatory mediators in response to brain injuryJ NeurosciYear: 2002226071608212122068
John GR,Lee SC,Song X,Rivieccio M,Brosnan CF,IL-1-regulated responses in astrocytes: relevance to injury and recoveryGliaYear: 20054916117610.1002/glia.2010915472994
Murphy PG,Grondin J,Altares M,Richardson PM,Induction of interleukin-6 in axotomized sensory neuronsJ NeurosciYear: 199515513051387623140
Ringheim GE,Burgher KL,Heroux JA,Interleukin-6 mRNA expression by cortical neurons in culture: evidence for neuronal sources of interleukin-6 production in the brainJ NeuroimmunolYear: 19956311312310.1016/0165-5728(95)00134-48550808
Goodman JC,Van M,Gopinath SP,Robertson CS,Pro-inflammatory and pro-apoptotic elements of the neuroinflammatory response are activated in traumatic brain injuryActa Neurochir SupplYear: 2008102437439 full_text. 19388362
Csuka E,Morganti-Kossmann MC,Lenzlinger PM,Joller H,Trentz O,Kossmann T,IL-10 levels in cerebrospinal fluid and serum of patients with severe traumatic brain injury: relationship to IL-6, TNF-alpha, TGF-beta1 and blood-brain barrier functionJ NeuroimmunolYear: 199910121122110.1016/S0165-5728(99)00148-410580806
Kossmann T,Hans VH,Imhof HG,Stocker R,Grob P,Trentz O,Intrathecal and serum interleukin-6 and the acute-phase response in patients with severe traumatic brain injuriesShockYear: 1995431131710.1097/00024382-199511000-000018595516
Hans VH,Kossmann T,Joller H,Otto V,Morganti-Kossmann MC,Interleukin-6 and its soluble receptor in serum and cerebrospinal fluid after cerebral traumaNeuroreportYear: 19991040941210203344
Singhal A,Baker AJ,Hare GM,Reinders FX,Schlichter LC,Moulton RJ,Association between cerebrospinal fluid interleukin-6 concentrations and outcome after severe human traumatic brain injuryJ NeurotraumaYear: 20021992993710.1089/08977150232031708712225653
Chiaretti A,Genovese O,Aloe L,Antonelli A,Piastra M,Polidori G,Interleukin 1beta and interleukin 6 relationship with paediatric head trauma severity and outcomeChilds Nerv SystYear: 20052118519310.1007/s00381-004-1032-115455248
Winter CD,Pringle AK,Clough GF,Church MK,Raised parenchymal interleukin-6 levels correlate with improved outcome after traumatic brain injuryBrainYear: 200412731532010.1093/brain/awh03914645145
Chiaretti A,Antonelli A,Mastrangelo A,Pezzotti P,Tortorolo L,Tosi F,Interleukin-6 and nerve growth factor upregulation correlates with improved outcome in children with severe traumatic brain injuryJ NeurotraumaYear: 20082522523410.1089/neu.2007.040518352836
Arand M,Melzner H,Kinzl L,Bruckner UB,Gebhard F,Early inflammatory mediator response following isolated traumatic brain injury and other major trauma in humansLangenbecks Arch SurgYear: 200138624124810.1007/s00423010020411466564
Harris TB,Ferrucci L,Tracy RP,Corti MC,Wacholder S,Ettinger WH Jr,Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderlyAm J MedYear: 199910650651210.1016/S0002-9343(99)00066-210335721
Oto J,Suzue A,Inui D,Fukuta Y,Hosotsubo K,Torii M,Plasma proinflammatory and anti-inflammatory cytokine and catecholamine concentrations as predictors of neurological outcome in acute stroke patientsJ AnesthYear: 20082220721210.1007/s00540-008-0639-x18685925
Stangl M,Zerkaulen T,Theodorakis J,Illner W,Schneeberger H,Land W,Influence of brain death on cytokine release in organ donors and renal transplantsTransplant ProcYear: 2001331284128510.1016/S0041-1345(00)02479-911267293
Sullivan NJ,Sasser AK,Axel AE,Vesuna F,Raman V,Ramirez N,Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cellsOncogeneYear: 2009282940294710.1038/onc.2009.18019581928
Fernandez-Real JM,Vayreda M,Richart C,Gutierrez C,Broch M,Vendrell J,Circulating interleukin 6 levels, blood pressure, and insulin sensitivity in apparently healthy men and womenJ Clin Endocrinol MetabYear: 2001861154115910.1210/jc.86.3.115411238501
Wetmore JB,Lovett DH,Hung AM,Cook-Wiens G,Mahnken JD,Sen S,Associations of interleukin-6, C-reactive protein and serum amyloid A with mortality in haemodialysis patientsNephrology (Carlton)Year: 20081359360010.1111/j.1440-1797.2008.01021.x18826487
Ali C,Nicole O,Docagne F,Lesne S,MacKenzie ET,Nouvelot A,Ischemia-induced interleukin-6 as a potential endogenous neuroprotective cytokine against NMDA receptor-mediated excitotoxicity in the brainJ Cereb Blood Flow MetabYear: 20002095696610.1097/00004647-200006000-0000810894179
Carlson NG,Wieggel WA,Chen J,Bacchi A,Rogers SW,Gahring LC,Inflammatory cytokines IL-1 alpha, IL-1 beta, IL-6, and TNF-alpha impart neuroprotection to an excitotoxin through distinct pathwaysJ ImmunolYear: 19991633963396810490998
Penkowa M,Giralt M,Carrasco J,Hadberg H,Hidalgo J,Impaired inflammatory response and increased oxidative stress and neurodegeneration after brain injury in interleukin-6-deficient miceGliaYear: 20003227128510.1002/1098-1136(200012)32:3<271::AID-GLIA70>3.0.CO;2-511102968
Zweig MH,Campbell G,Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicineClin ChemYear: 1993395615778472349
Cavaillon JM,Cytokines and macrophagesBiomed PharmacotherYear: 19944844545310.1016/0753-3322(94)90005-17858154
Beagley KW,Elson CO,Cells and cytokines in mucosal immunity and inflammationGastroenterol Clin North AmYear: 1992213473661512047
Zhang Y,Lin JX,Vilcek J,Synthesis of interleukin 6 (interferon-beta 2/B cell stimulatory factor 2) in human fibroblasts is triggered by an increase in intracellular cyclic AMPJ Biol ChemYear: 1988263617761822452159
Yoshizaki K,Nishimoto N,Matsumoto K,Tagoh H,Taga T,Deguchi Y,Interleukin 6 and expression of its receptor on epidermal keratinocytesCytokineYear: 1990238138710.1016/1043-4666(90)90069-62129417
Loppnow H,Libby P,Comparative analysis of cytokine induction in human vascular endothelial and smooth muscle cellsLymphokine ResYear: 198982932992789322
Hensler T,Sauerland S,Bouillon B,Raum M,Rixen D,Helling HJ,Association between injury pattern of patients with multiple injuries and circulating levels of soluble tumor necrosis factor receptors, interleukin-6 and interleukin-10, and polymorphonuclear neutrophil elastaseJ TraumaYear: 20025296297010.1097/00005373-200205000-0002311988666
Zemlan FP,Jauch EC,Mulchahey JJ,Gabbita SP,Rosenberg WS,Speciale SG,C-tau biomarker of neuronal damage in severe brain injured patients: association with elevated intracranial pressure and clinical outcomeBrain ResYear: 200294713113910.1016/S0006-8993(02)02920-712144861
Pelinka LE,Kroepfl A,Leixnering M,Buchinger W,Raabe A,Redl H,GFAP versus S100B in serum after traumatic brain injury: relationship to brain damage and outcomeJ NeurotraumaYear: 2004211553156110.1089/neu.2004.21.155315684648
Herrmann M,Jost S,Kutz S,Ebert AD,Kratz T,Wunderlich MT,Temporal profile of release of neurobiochemical markers of brain damage after traumatic brain injury is associated with intracranial pathology as demonstrated in cranial computerized tomographyJ NeurotraumaYear: 20001711312210.1089/neu.2000.17.11310709869
Shore PM,Thomas NJ,Clark RS,Adelson PD,Wisniewski SR,Janesko KL,Continuous versus intermittent cerebrospinal fluid drainage after severe traumatic brain injury in children: effect on biochemical markersJ NeurotraumaYear: 2004211113112210.1089/neu.2004.21.111315453982
Dash PK,Zhao J,Hergenroeder GW,Moore AN,Biomarkers fof the diagnosis, prognosis, and evaluation of treatment efficacy for traumatic brain injuryNeurotherapeutics710011410.1016/j.nurt.2009.10.01920129502
Dash PK,Redell JB,Hergenroeder GW,Zhao J,Clifton GL,Moore AN,Serum ceruloplasmin and copper are early biomarkers of elevated intracranial pressureJ Neurosci Res in press .

Figures

[Figure ID: F1]
Figure 1 

Identification of serum IL-6 as a marker of elevated ICP by antibody arrays. A. Time course of ICP in patients classified as having elevated ICP (ICP ? 25 mm Hg) versus that recorded in patients whose ICP remained below 20 mm Hg for the duration of the sampling period. B. Representative picture of a Ray Biosciences Cytokine array showing the immunoreactivity of interleukin family members in pooled samples (n = 7/pool) from healthy volunteers, TBI patients with elevated ICP, and TBI patients whose ICP remained below 20 mm Hg for the duration of the 5 day sampling period. C. Summary data (presented as % healthy volunteer(HV)) showing that the relative signal of IL-6 is significantly increased in patients with ICP ? 25 mm Hg compared to patients whose ICP remained below 20 mm Hg throughout the study period. Data is presented as mean ? SEM. ?, significant difference by two-way ANOVA.



[Figure ID: F2]
Figure 2 

Early increase in serum IL-6 can be used to stratify TBI patients based on risk for developing elevated ICP. A. Time course of ICP in patients classified as having elevated ICP (ICP > 25 mm Hg) versus that recorded in patients whose ICP remained below 20 mm Hg for the duration of the sampling period. B. Standard curve showing the relationship between increasing IL-6 concentrations and the mean fluorescent intensity (MFI) detected by Luminex analysis. C. Summary data showing the levels of IL-6 detected in the serum of healthy volunteers (HV), from TBI patients with elevated ICP (ICP > 25 mm Hg), and from patients whose ICP remained below 20 mm Hg throughout the study period. D. Luminex data organized based on time of sample withdrawal relative to the subsequent increase in ICP. Day 0 represents the time point at which the ICP was recorded to surpass 25 mm Hg. Each patient with an elevation in ICP was paired with a patient whose ICP remained ?20 mm Hg throughout the study period. Data is presented as mean ? SEM. ?, significant difference by two-way ANOVA.



[Figure ID: F3]
Figure 3 

Representative ICP profiles for TBI patients. ICP profiles for TBI patients whose ICP A. remained ?20 mm Hg throughout the 5 day study period and B. elevated to ?25 mm Hg. Dotted line represents 20 mm Hg, the threshold for clinical intervention.



[Figure ID: F4]
Figure 4 

Orthopedic injury increases serum IL-6 levels. A. Summary data showing the mean serum IL-6 concentrations for healthy volunteers (HV) and orthopedic injury patients. Serum IL-6 levels were significantly lower in orthopedic injury patients compared to TBI patients with B. isolated brain injury and C. polytrauma. Data is presented as mean ? SEM. *, P < 0.05.



Tables
[TableWrap ID: T1] Table 1 

Demographic and clinical information for subjects used for pooled samples for RayBioscience assays.


Healthy Volunteers (n = 14) ICP ?20 mm Hg (n = 14) ICP ?25 mm Hg (n = 14)
Age range 22-39 years 15-48 years 14-56 years

Age (average) 26.2 ? 4.7 years 24.4 ? 9.2 years 28.1 ? 14.8 years

Gender 11 male 12 male 12 male
3 female 2 female 2 female

Race 10 Caucasians 11 Caucasians 12 Caucasians
3 African-Americans 3 African-Americans 1 African-American
1 Asian 1 Asian

Ethnicity 11 non-hispanics 9 non-hispanics 6 non-hispanics
3 non-hispanics 5 hispanics 8 hispanics


Apache II score N/A 18.8 ? 6.0 20.2 ? 4.1

ISS N/A 27.9 ? 6.4 23.0 ? 8.4

Data is presented as mean ? SEM.


[TableWrap ID: T2] Table 2 

Demographic and clinical information for subjects used for Luminex analysis. Data is presented as mean ? SEM.


Healthy Volunteers (n = 10) ICP ?20 mm Hg
(n = 9)
ICP ?25 mm Hg (n = 10)
Age range 20-39 years 19-51 years 14-54 years

Age (average) 26.5 ? 5.5 years 29.5 ? 12.1 years 29.3 ? 11.2 years

Gender 8 male 6 male 9 male
2 female 3 female 1 female

Race 8 Caucasians 8 Caucasians 9 Caucasians
1 African-Americans 1 African-Americans 1 African-American
1 Asian

Ethnicity 5 non-hispanics 6 non-hispanics 6 non-hispanics
5 non-hispanics 3 hispanics 4 hispanics

Apache II score N/A 17.6 ? 3.7 21.2 ? 3.5

ISS N/A 23.6 ? 5.4 19.8 ? 3.6

Therapy intensity level
first 24 hr N/A 4.0 ? 1.8 5.1 ? 4.1
72-120 hr N/A 3.2 ? 1.8 5.2 ? 4.0

Mortality at time of discharge N/A 0/9 (0%) 2/10 (20%)

Mechanism of injury N/A
motorcycle collision 3/9 (33%) 3/10 (30%)
motor vehicle accident 5/9 (55%)a 5/10 (50%)
fall 0/9 (0%) 2/10 (20%)b
assault 1/9 (11%) 0/10 (0%)

Initial CT resultsc N/A
skull fracture 5/9 (56%) 5/10 (50%)
subarachnoid hemorrhage 6/9 (67%) 7/10 (70%)
epidural hematoma 3/9 (33%) 1/10 (10%)
subdural hematoma 3/9 (33%) 8/10 (80%)
intraventricular hemorrhage 4/9 (44%) 3/10 (33%)
contusion 7/9 (78%) 8/10 (80%)
midline shift 3/9 (33%) 3/10 (30%)
edema 5/9 (56%) 3/10 (30%)
diffuse axonal injury 0/9 (0%) 1/10 (10%)

a, one subject was assaulted after motor vehicle accident

b, one subject fell off a moving vehicle

c, some patients may present with more than one pathology.


[TableWrap ID: T3] Table 3 

Comparison of IL-6 concentrations detected in 20 randomly chosen serum samples detected using Luminex and conventional ELISA analyses.


Sample Luminex ELISA Sample Luminex ELISA
1 69.8 pg/ml 76.3 pg/ml 11 130.8 pg/ml 153.1 pg/ml

2 62.5 pg/ml 69.4 pg/ml 12 902.1 pg/ml 54.7 pg/ml

3 883.5 pg/ml >600 pg/ml 13 268.2 pg/ml 322.2 pg/ml

4 116.2 pg/ml 148.6 pg/ml 14 47.4 pg/ml 57.5 pg/ml

5 110.1 pg/ml 179.7 pg/ml 15 28.9 pg/ml 61.7 pg/ml

6 154.6 pg/ml 172.5 pg/ml 16 204.4 pg/ml 257.0 pg/ml

7 43.6 pg/ml 63.5 pg/ml 17 57.2 pg/ml 93.4 pg/ml

8 83.5 pg/ml 124.2 pg/ml 18 59.7 pg/ml 89.7 pg/ml

9 883.5 pg/ml >600 pg/ml 19 160.1 pg/ml 204.5 pg/ml

10 28.1 pg/ml 43.5 pg/ml 20 30.7 pg/ml 36.9 pg/ml

[TableWrap ID: T4] Table 4 

Diagnostic accuracy of IL-6 for predicting subsequent elevations in ICP.


Maximum ICP (mm Hg) ELISA (pg/ml IL-6) Classification Actual
1 NA undetectable HV HV

2 NA undetectable HV HV

3 NA undetectable HV HV

4 NA 2.01 HV HV

5 NA undetectable HV HV

6 NA undetectable HV HV

7 NA undetectable HV HV

8 20 76.31 ICP ? 20 mm Hg ICP ? 20 mm Hg

9 16 148.58 ICP ? 25 mm Hg ICP ? 20 mm Hg

10 20 54.66 ICP ? 20 mm Hg ICP ? 20 mm Hg

11 19 63.53 ICP ? 20 mm Hg ICP ? 20 mm Hg

12 20 251.51 ICP ? 25 mm Hg ICP ? 20 mm Hg

13 16 57.48 ICP ? 20 mm Hg ICP ? 20 mm Hg

14 19 93.45 ICP ? 20 mm Hg ICP ? 20 mm Hg

15 20 94.6 ICP ? 20 mm Hg ICP ? 20 mm Hg

16 30 188.17 ICP ? 25 mm Hg ICP ? 25 mm Hg

17 28 573.01 ICP ? 25 mm Hg ICP ? 25 mm Hg

18 26 152.78 ICP ? 25 mm Hg ICP ? 25 mm Hg

19 31 >600 ICP ? 25 mm Hg ICP ? 25 mm Hg

20 31 172.46 ICP ? 25 mm Hg ICP ? 25 mm Hg

21 38 >600 ICP ? 25 mm Hg ICP ? 25 mm Hg

22 30 43.52 ICP ? 20 mm Hg ICP ? 25 mm Hg

Blinded samples, taken within the first 16 hr of injury (or from paired healthy volunteers), were analyzed for IL-6 content. HV: healthy volunteer


[TableWrap ID: T5] Table 5 

Diagnostic accuracy of IL-6 for predicting subsequent elevations in ICP in patients with polytrauma.


Maximum ICP (mm Hg) IL-6 (pg/ml) Classification Actual
1 NA undetectable HV HV

2 NA 2.06 HV HV

3 NA 1.44 HV HV

4 11 >600 ICP ? 25 mm Hg ICP ? 20 mm Hg

5 16 140.28 ICP ? 25 mm Hg ICP ? 20 mm Hg

6 20 50.01 ICP ? 20 mm Hg ICP ? 20 mm Hg

7 20 518.70 ICP ? 25 mm Hg ICP ? 20 mm Hg

8 12 75.00 ICP ? 20 mm Hg ICP ? 20 mm Hg

9 34 85.21 ICP ? 20 mm Hg ICP ? 25 mm Hg

10 32 342.89 ICP ? 25 mm Hg ICP ? 25 mm Hg

11 28 189.76 ICP ? 25 mm Hg ICP ? 25 mm Hg

12 38 30.91 ICP ? 20 mm Hg ICP ? 25 mm Hg

13 34 236.90 ICP ? 25 mm Hg ICP ? 25 mm Hg

14 26 466.18 ICP ? 25 mm Hg ICP ? 25 mm Hg

Blinded samples taken within the first 16 hr of injury (or from paired healthy volunteers) were analyzed for IL-6 content. Serum IL-6 concentrations could be used to correctly identify only 6 of the 11 polytrauma patients tested (54%). HV: healthy volunteer.


[TableWrap ID: T6] Table 6 

Serum IL-6 levels in orthopedic injury patients without diagnosis of brain injury.


Patient Injury ELISA (pg/ml IL-6)
1 Right metacarpel fracture 14.68

2 Open tibia/fibia fracture, fractures of lumbar vertebrae and coccyx 100.89

3 Crush injury to right leg 24.63

4 Communited fracture of right femur midshaft 53.88

5 Bimalleolar fracture of ankle 1.71

6 Crushed foot, closed tibia and fibia fracture 31.93

7 Trimalleolar fracture of right ankle 7.21

Samples were taken within the first 24 hr of injury.



Article Categories:
  • Research


Previous Document:  A massive ovarian mucinous cystadenoma: a case report.
Next Document:  The first set of EST resource for gene discovery and marker development in pigeonpea (Cajanus cajan ...